PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy

BACKGROUND: Despite advances in treatment of patients with non-small cell lung cancer, carriers of certain genetic alterations are prone to failure. One such factor frequently mutated, is the tumor suppressor PTEN. These tumors are supposed to be more resistant to radiation, chemo- and immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Thomas, Hartmann, Oliver, Reissland, Michaela, Prieto-Garcia, Cristian, Klann, Kevin, Pahor, Nikolett, Schülein-Völk, Christina, Baluapuri, Apoorva, Polat, Bülent, Abazari, Arya, Gerhard-Hartmann, Elena, Kopp, Hans-Georg, Essmann, Frank, Rosenfeldt, Mathias, Münch, Christian, Flentje, Michael, Diefenbacher, Markus E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044846/
https://www.ncbi.nlm.nih.gov/pubmed/35477555
http://dx.doi.org/10.1186/s13578-022-00778-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044846/
https://www.ncbi.nlm.nih.gov/pubmed/35477555
http://dx.doi.org/10.1186/s13578-022-00778-7

Ejemplares similares